The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis

Purpose: Recent studies show that ductal carcinoma in situ (DCIS) accompanying HER2+ breast cancer can be completely eradicated following neoadjuvant systemic therapy in up to 52 %. We aimed to determine the complete response rate of DCIS in triple-negative breast cancer (TNBC) patients in a nationw...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva L. Claassens, Roxanne A.W. Ploumen, Loes F.S. Kooreman, Maartje A.C.E. van Kats, Sabine Siesling, Thiemo J.A. van Nijnatten, Marjolein L. Smidt
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Breast
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S096097762500044X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343526734659584
author Eva L. Claassens
Roxanne A.W. Ploumen
Loes F.S. Kooreman
Maartje A.C.E. van Kats
Sabine Siesling
Thiemo J.A. van Nijnatten
Marjolein L. Smidt
author_facet Eva L. Claassens
Roxanne A.W. Ploumen
Loes F.S. Kooreman
Maartje A.C.E. van Kats
Sabine Siesling
Thiemo J.A. van Nijnatten
Marjolein L. Smidt
author_sort Eva L. Claassens
collection DOAJ
description Purpose: Recent studies show that ductal carcinoma in situ (DCIS) accompanying HER2+ breast cancer can be completely eradicated following neoadjuvant systemic therapy in up to 52 %. We aimed to determine the complete response rate of DCIS in triple-negative breast cancer (TNBC) patients in a nationwide cohort and to assess clinicopathological variables associated with response. Furthermore, the impact on surgical treatment after neoadjuvant chemotherapy (NACT) was investigated. Methods: Women diagnosed with TNBC, treated with NACT followed by surgery, between 2010 and 2020, were selected from the Netherlands Cancer Registry (NCR). Pre-NACT and postoperative pathology reports were obtained from Palga, the Dutch nationwide pathology databank, to determine presence of DCIS. Clinicopathological factors associated with DCIS response were investigated using uni- and multivariable logistic regression analysis. Results: In total, 4494 patients were included. A DCIS component was present in the pre-NACT biopsy of 442 (9.8 %) patients. Pathologic complete response of the DCIS component was achieved in 53.6 % of these patients. The presence of calcifications in the pre-NACT biopsy was associated with a lower chance of DCIS response in univariable logistic regression analysis (OR 0.52, CI 95 % 0.27–0.98, p = 0.04). In multivariable analysis, no statistically significant associations were found between DCIS response and clinicopathological variables. Mastectomy rates were higher in case of IBC + DCIS compared to IBC (53.4 % vs 40.1 %, p < 0.001). Conclusion: Pathologic complete response of DCIS to NACT occurred in 53.6 % of TNBC patients. Future studies are required to be able to predict DCIS response based on clinicopathological variables and imaging.
format Article
id doaj-art-b8bfba8dfc8048308e0fd043965e567a
institution Kabale University
issn 1532-3080
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series Breast
spelling doaj-art-b8bfba8dfc8048308e0fd043965e567a2025-08-20T03:42:56ZengElsevierBreast1532-30802025-04-018010442510.1016/j.breast.2025.104425The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysisEva L. Claassens0Roxanne A.W. Ploumen1Loes F.S. Kooreman2Maartje A.C.E. van Kats3Sabine Siesling4Thiemo J.A. van Nijnatten5Marjolein L. Smidt6Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW – Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Corresponding author. Department of Surgery Maastricht University Medical Centre+ P.O. Box 616 6200 MD Maastricht the Netherlands.Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW – Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the NetherlandsGROW – Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Pathology, Maastricht University Medical Centre+, Maastricht, the NetherlandsDepartment of Medical Oncology, Maastricht University Medical Centre+, Maastricht, the NetherlandsDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the NetherlandsGROW – Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, the NetherlandsDepartment of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW – Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the NetherlandsPurpose: Recent studies show that ductal carcinoma in situ (DCIS) accompanying HER2+ breast cancer can be completely eradicated following neoadjuvant systemic therapy in up to 52 %. We aimed to determine the complete response rate of DCIS in triple-negative breast cancer (TNBC) patients in a nationwide cohort and to assess clinicopathological variables associated with response. Furthermore, the impact on surgical treatment after neoadjuvant chemotherapy (NACT) was investigated. Methods: Women diagnosed with TNBC, treated with NACT followed by surgery, between 2010 and 2020, were selected from the Netherlands Cancer Registry (NCR). Pre-NACT and postoperative pathology reports were obtained from Palga, the Dutch nationwide pathology databank, to determine presence of DCIS. Clinicopathological factors associated with DCIS response were investigated using uni- and multivariable logistic regression analysis. Results: In total, 4494 patients were included. A DCIS component was present in the pre-NACT biopsy of 442 (9.8 %) patients. Pathologic complete response of the DCIS component was achieved in 53.6 % of these patients. The presence of calcifications in the pre-NACT biopsy was associated with a lower chance of DCIS response in univariable logistic regression analysis (OR 0.52, CI 95 % 0.27–0.98, p = 0.04). In multivariable analysis, no statistically significant associations were found between DCIS response and clinicopathological variables. Mastectomy rates were higher in case of IBC + DCIS compared to IBC (53.4 % vs 40.1 %, p < 0.001). Conclusion: Pathologic complete response of DCIS to NACT occurred in 53.6 % of TNBC patients. Future studies are required to be able to predict DCIS response based on clinicopathological variables and imaging.http://www.sciencedirect.com/science/article/pii/S096097762500044XDuctal carcinoma in situNeoadjuvant chemotherapyPathologic complete responseTriple-negative breast cancer
spellingShingle Eva L. Claassens
Roxanne A.W. Ploumen
Loes F.S. Kooreman
Maartje A.C.E. van Kats
Sabine Siesling
Thiemo J.A. van Nijnatten
Marjolein L. Smidt
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
Breast
Ductal carcinoma in situ
Neoadjuvant chemotherapy
Pathologic complete response
Triple-negative breast cancer
title The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
title_full The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
title_fullStr The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
title_full_unstemmed The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
title_short The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
title_sort effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple negative breast cancer patients a nationwide analysis
topic Ductal carcinoma in situ
Neoadjuvant chemotherapy
Pathologic complete response
Triple-negative breast cancer
url http://www.sciencedirect.com/science/article/pii/S096097762500044X
work_keys_str_mv AT evalclaassens theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT roxanneawploumen theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT loesfskooreman theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT maartjeacevankats theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT sabinesiesling theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT thiemojavannijnatten theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT marjoleinlsmidt theeffectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT evalclaassens effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT roxanneawploumen effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT loesfskooreman effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT maartjeacevankats effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT sabinesiesling effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT thiemojavannijnatten effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis
AT marjoleinlsmidt effectofneoadjuvantchemotherapyonductalcarcinomainsituintriplenegativebreastcancerpatientsanationwideanalysis